They Just Don't Get...
Health Care: Drugs
EntreMed Inc. (ENMD: NASDAQ)
$2.03 0.07 | 3.57%
06/04/12 - 03:59 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 1.94M | 3.69M | 5.28M | 7.48M |
| Cost of Sales | -38.12K | -70.36K | -73.84K | 254.42K |
| Gross Operating Profit | 1.98M | 3.76M | 5.36M | 7.22M |
| Selling, General, and Administrative Expenses | 3.05M | 3.40M | 4.10M | 7.76M |
| Research & Development | 3.46M | 4.83M | 7.90M | 20.07M |
| Operating Income before D & A (EBITDA) | -4.53M | -4.46M | -6.65M | -20.61M |
| Depreciation & Amortization | 38.12K | 70.36K | 73.84K | -254.42K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | 9.50K | -26.26K | -1.23K | 710.68K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -4.56M | -7.56M | -6.72M | -21.65M |
| Interest Expense | 0.00 | 540.22K | 1.49M | 2.22M |
| Pre-Tax Income | -4.56M | -8.10M | -8.22M | -23.86M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -4.56M | -8.10M | -8.22M | -23.86M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -4.56M | -8.10M | -8.22M | -23.86M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -4.56M | -8.10M | -8.22M | -23.86M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-4.56M | -5.10M | -8.22M | -21.86M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -5.56M | -9.11M | -9.22M | -24.87M |
| Basic EPS from Continuing Ops. | -0.47 | -0.94 | -1.21 | -3.19 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.47 | -0.94 | -1.21 | -3.19 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.47 | -0.94 | -1.21 | -3.19 |
| Basic Normalized Net Income/Share | -0.47 | -0.59 | -1.21 | -2.92 |
| EPS fr Continuing Ops. | -0.47 | -0.94 | -1.21 | -3.19 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.47 | -0.94 | -1.21 | -3.19 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.47 | -0.94 | -1.21 | -3.19 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.47 | -0.59 | -1.21 | -2.92 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ENMD
- Portfolio NameUser Type
- Contributor6 Drug Stocks Unworthy of B...
- UserBeaver
- Contributor10 Stocks Under $5 Outperfo...
- ContributorStocks Under $5 at Risk of ...
- UserDorkingLad Portfolio 1
- Usersmallbiz
- Usersteves #1
- UserThe Investment Psychologist...
- Userdrweik Portfolio 1
- UserJake's Portfolio 1
Latest ENMD Headlines from TheStreet
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- 10 Stocks Under $5 Outperforming in 2012 01.31.12 | 05:01 am
- Stocks Under $5 at Risk of Bankruptcy 06.08.11 | 06:06 am
- Biotech Sector Weekly Rewind 11.20.10 | 08:11 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Sprint Nextel, Palm: Early Volume Plays 04.19.10 | 07:04 am
- ThermoGenesis, Power-One: Early Volume Plays 02.05.10 | 07:02 am
- Netlist, EntreMed: Midday Volume Plays 12.14.09 | 02:12 pm
- ExpressJet, Entremed: Midday Volume Plays 11.16.09 | 02:11 pm
Press Releases for ENMD
- EntreMed Appoints Interim CEO - PR Newswire 04.03.12 | 07:04 am
- EntreMed Initiates Plans For China Office - PR Newswire 03.05.12 | 02:03 pm
- EntreMed Completes Strategic Financing - PR Newswire 02.06.12 | 07:02 am
- Biotech Leaders Wei-Wu He, Ph.D And Tak W. Mak, Ph.D Join EntreMed's Board Of Directors - PR Newswire 02.06.12 | 07:02 am
- EntreMed's ENMD-2076 Demonstrates Promising Activity In A Phase 2 Study In Platinum-Resistant Ovarian Cancer Patients - PR Newswire 10.03.11 | 07:10 am
- EntreMed Enters Into $7.5 Million Equity Facility And Initiates $1.1 Million Drawdown - PR Newswire 06.28.11 | 05:06 pm
- Selected Value Therapeutics Exercises Right To Develop And Commercialize Enmd-2076 In China - PR Newswire 06.07.11 | 11:06 am
- EntreMed's ENMD-2076 Demonstrates Clinical Activity In Recurrent, Platinum-Resistant Ovarian Cancer Patients - PR Newswire 06.03.11 | 03:06 pm
- EntreMed Reports Fourth Quarter And Year-End 2009 Financial Results - PR Newswire 03.29.10 | 04:03 pm
Partner Headlines for ENMD
- China Biotech In Review: GSK Explores All Paths To Increase China Presence - Seeking Alpha 03.11.12 | 07:03 am
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO - Seeking Alpha 09.12.10 | 09:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress - Fox Business 08.16.10 | 12:08 pm
